Leo Raisis, MD
Orthopaedic Surgery · Newark, DENPI 1629058540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Medacta USA, Inc. at 33.1% of the total. Reporting peaked in 2019 at $167 and has fallen 76.3% since, to $40 in 2024. That places this record below the midpoint for orthopaedic surgery clinicians in DE, where the typical reported total is $6,222.
Across 14 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medacta USA, Inc.$110
- Johnson & Johnson$102
- Pacira Therapeutics, Inc.$52
- Ferring Pharmaceuticals Inc.$47
- Zimmer Biomet$21
What the payments were for
- Food & beverage$331100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medacta USA, Inc. | 1 | $110 |
| Johnson & Johnson | 7 | $102 |
| Pacira Therapeutics, Inc. | 2 | $52 |
| Ferring Pharmaceuticals Inc. | 3 | $47 |
| Zimmer Biomet | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EFFICIENCY$110
How this compares
$331 in reported general payments places this provider in the 15th percentile of 70 orthopaedic surgery providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 15 | $761 |
| Meloxicam | 38 | $220 |
| Prednisone | 47 | $146 |
| Cephalexin | 39 | $144 |
| Methylprednisolone | 12 | $113 |
| Gabapentin | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Newark
- Jeremie AxeNewark$179K
- Kenneth LingenfelterNewark$67K
- Drew BradyNewark$64K
- Barry SharpeNewark$26K
- Samuel MeaseNewark$16K
- Adam SantoroNewark$9K
- Elliott LeitmanNewark$4K
- James CostanzoNewark$3K
- Matthew HandlingNewark$3K
- Christopher CasscellsNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.